Rocket Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Rocket Pharmaceuticals, Inc. (RCKT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $75.02 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-07
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $32.56M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $27.14M, a 450.33% increase year-over-year.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $8.22M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $7.09M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $75.02M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$66.06M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$31.68M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-12-31 | $32.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $59.70M derived: sum of 2 quarters · filed 2018-03-07 | $67.92M derived: sum of 3 quarters · filed 2018-03-07 | $75.02M 10-K · filed 2018-03-07 |
| 2017-09-30 | $27.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $35.36M derived: sum of 2 quarters · filed 2017-11-08 | $42.45M 10-Q · filed 2017-11-08 | $172.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-06-30 | $8.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $15.32M 10-Q · filed 2017-08-03 | -$26.96M derived: sum of 3 quarters · filed 2018-03-07 | -$22.03M derived: sum of 4 quarters · filed 2018-03-07 |
| 2017-03-31 | $7.09M 10-Q · filed 2017-05-10 | -$35.19M derived: sum of 2 quarters · filed 2018-03-07 | -$30.26M derived: sum of 3 quarters · filed 2018-03-07 | -$46.62M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-12-31 | -$42.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$37.35M derived: sum of 2 quarters · filed 2018-03-07 | -$53.72M derived: sum of 3 quarters · filed 2018-03-07 | -$66.06M 10-K · filed 2018-03-07 |
| 2016-09-30 | $4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$11.44M derived: sum of 2 quarters · filed 2017-11-08 | -$23.78M 10-Q · filed 2017-11-08 | -$26.02M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | -$16.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$28.71M 10-Q · filed 2017-08-03 | -$30.95M derived: sum of 3 quarters · filed 2017-08-03 | -$60.35M derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | -$12.34M 10-Q · filed 2017-05-10 | -$14.58M derived: sum of 2 quarters · filed 2017-05-10 | -$43.99M derived: sum of 3 quarters · filed 2017-05-10 | -$44.02M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$31.64M derived: sum of 2 quarters · filed 2017-03-16 | -$31.68M derived: sum of 3 quarters · filed 2017-03-16 | -$31.68M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$29.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$29.43M derived: sum of 2 quarters · filed 2016-11-09 | -$29.43M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$30.00K 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |